Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Welcome The Hill’s annual list of Top Lobbyists. President Trump’s return to the White House brought a whirlwind of policy ...

Once construction is complete in 2032, the company plans on creating some of its "biggest medicines" at the new facility.

Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply ...

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...

Eli Lilly plans to start work next year on a facility that will produce orforglipron, officials announced Tuesday in Huntsville.

Health-care companies fell as traders weighed risks in a wave of deal activity. Pfizer joined Big Pharma rivals hunting for novel weight loss drugs in the Chinese biotech sector.